Molecular regulation of pancreatic stellate cell function

<p>Abstract</p> <p>Until now, no specific therapies are available to inhibit pancreatic fibrosis, a constant pathological feature of chronic pancreatitis and pancreatic cancer. One major reason is the incomplete knowledge of the molecular principles underlying fibrogenesis in the p...

Full description

Bibliographic Details
Main Author: Jaster Robert
Format: Article
Language:English
Published: BMC 2004-10-01
Series:Molecular Cancer
Online Access:http://www.molecular-cancer.com/content/3/1/26
id doaj-43360f31d37e4b00968346b2e3925229
record_format Article
spelling doaj-43360f31d37e4b00968346b2e39252292020-11-24T21:10:28ZengBMCMolecular Cancer1476-45982004-10-01312610.1186/1476-4598-3-26Molecular regulation of pancreatic stellate cell functionJaster Robert<p>Abstract</p> <p>Until now, no specific therapies are available to inhibit pancreatic fibrosis, a constant pathological feature of chronic pancreatitis and pancreatic cancer. One major reason is the incomplete knowledge of the molecular principles underlying fibrogenesis in the pancreas. In the past few years, evidence has been accumulated that activated pancreatic stellate cells (PSCs) are the predominant source of extracellular matrix (ECM) proteins in the diseased organ. PSCs are vitamin A-storing, fibroblast-like cells with close morphological and biochemical similarities to hepatic stellate cells (also known as Ito-cells). In response to profibrogenic mediators such as various cytokines, PSCs undergo an activation process that involves proliferation, exhibition of a myofibroblastic phenotype and enhanced production of ECM proteins. The intracellular mediators of activation signals, and their antagonists, are only partially known so far. Recent data suggest an important role of enzymes of the mitogen-activated protein kinase family in PSC activation. On the other hand, ligands of the nuclear receptor PPARγ (peroxisome proliferator-activated receptor γ) stimulate maintenance of a quiescent PSC phenotype. In the future, targeting regulators of the PSC activation process might become a promising approach for the treatment of pancreatic fibrosis.</p> http://www.molecular-cancer.com/content/3/1/26
collection DOAJ
language English
format Article
sources DOAJ
author Jaster Robert
spellingShingle Jaster Robert
Molecular regulation of pancreatic stellate cell function
Molecular Cancer
author_facet Jaster Robert
author_sort Jaster Robert
title Molecular regulation of pancreatic stellate cell function
title_short Molecular regulation of pancreatic stellate cell function
title_full Molecular regulation of pancreatic stellate cell function
title_fullStr Molecular regulation of pancreatic stellate cell function
title_full_unstemmed Molecular regulation of pancreatic stellate cell function
title_sort molecular regulation of pancreatic stellate cell function
publisher BMC
series Molecular Cancer
issn 1476-4598
publishDate 2004-10-01
description <p>Abstract</p> <p>Until now, no specific therapies are available to inhibit pancreatic fibrosis, a constant pathological feature of chronic pancreatitis and pancreatic cancer. One major reason is the incomplete knowledge of the molecular principles underlying fibrogenesis in the pancreas. In the past few years, evidence has been accumulated that activated pancreatic stellate cells (PSCs) are the predominant source of extracellular matrix (ECM) proteins in the diseased organ. PSCs are vitamin A-storing, fibroblast-like cells with close morphological and biochemical similarities to hepatic stellate cells (also known as Ito-cells). In response to profibrogenic mediators such as various cytokines, PSCs undergo an activation process that involves proliferation, exhibition of a myofibroblastic phenotype and enhanced production of ECM proteins. The intracellular mediators of activation signals, and their antagonists, are only partially known so far. Recent data suggest an important role of enzymes of the mitogen-activated protein kinase family in PSC activation. On the other hand, ligands of the nuclear receptor PPARγ (peroxisome proliferator-activated receptor γ) stimulate maintenance of a quiescent PSC phenotype. In the future, targeting regulators of the PSC activation process might become a promising approach for the treatment of pancreatic fibrosis.</p>
url http://www.molecular-cancer.com/content/3/1/26
work_keys_str_mv AT jasterrobert molecularregulationofpancreaticstellatecellfunction
_version_ 1716756440070225920